Refine by
Gastrointestinal Diseases Articles & Analysis: Older
38 news found
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. The associated patents broadly cover foundational elements for the rapid, ...
BioPharma: Microbiome therapeutics, anti-microbial resistance, personalised/stratified medicine, therapeutics for gastrointestinal and infectious diseases, immuno-oncology/autoimmune disease and metabolic health. ...
MOUNTAIN VIEW, Calif., May 26, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced that two posters were presented at Digestive Disease Week Conference held in San Diego in from May 21 through May 24. ...
Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug discovery programs in the area of ...
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan. On May 4, 2022, the Company’s Compensation Committee granted options to four new non-executive employees covering an aggregate of 140,000 shares ...
Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 ...
“We continue to be encouraged by the potential of LB1148 to protect gastrointestinal integrity and accelerate the return of postoperative GI function. ...
- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET. Participating from the Palisade Bio management team will be Tom Hallam, Ph.D., Chief ...
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that of Palisade Bio, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28–30, 2022. As part of the conference, a video webcast of the ...
Researchers describe rapid, low-cost drug development approach Paper also reports preclinical and early clinical data for LMN-101 A common food source has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments. Researchers at Lumen Bioscience report ...
(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons ...
MOUNTAIN VIEW, Calif., March 15, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced that two posters have been accepted for presentation at the upcoming Digestive Disease Week Conference to be held in San Diego in from May 21 through May 24. ...
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148” at The Next ...
Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that Robert McRae has joined the senior management team as Senior Vice President, Operations and Strategic Development. Rob is an accomplished industry veteran with a proven track record of execution who will be responsible ...
“We are very pleased with the updated preliminary results from the Phase 1/2 STAAR study and believe that isaralgagene civaparvovec gene therapy has the potential to be a compelling treatment option for patients with Fabry disease, who currently have a burdensome standard of care that requires regular and lifelong intravenous treatment, and that in many cases doesn’t ...
SIUT is a renowned, charitable institute, providing free state of the art medical treatment to all patients, regardless of background or wealth, facilitating the treatment of renal ailments, urological and nephrological conditions, oncological treatments, treatments of hepatic and gastrointestinal diseases, and organ transplantation. The small, portable and ...
Perrow was the chief executive officer of AsclepiX Therapeutics, Inc., an early-stage biotechnology company developing novel peptide therapeutics for indications in retinal diseases and oncology. She also served as an AsclepiX board member. Prior to this, Ms. Perrow was the chief executive officer of Alba Therapeutics, Inc., a clinical-stage biotechnology company developing novel ...
GI disorders include inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal disorders (FGID’s).1 GI dysfunctions are also prevalent during recovery from abdominal surgery which can lead to post-operative ileus (POI).2 Current motility technologies are typically limited in scope, invasive and only sample for a ...